Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology, a clinical-stage biotechnology company, announced a capital increase of 300,000 new shares on July 30, 2021, to Lincoln Park Capital Fund, LLC. This move raises the company's share capital to 54,956,224.33 EUR, represented by 15,793,956 shares. Following the capital increase, the total number of diluted shares stands at 17,716,379. The company focuses on developing CAR T therapies for cancer treatment and is headquartered in Belgium.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) will report its first half 2021 financial and operating results on August 4, 2021. A conference call is scheduled for August 5 at 2 p.m. CEST / 8 a.m. EDT to discuss these findings and updates on recent progress. Celyad focuses on developing CAR T therapies for cancer, including both allogeneic and autologous candidates, supported by funding from the Walloon Region, Belgium. The company warns that forward-looking statements may involve risks, including those associated with the COVID-19 pandemic.
Celyad Oncology (CYAD) provided updates on its CAR T therapies during a recent research and development day. The Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma showed promising dose-dependent engraftment with no reported Graft-versus-Host disease. The IND application for CYAD-203, a first-in-class IL-18-armored CAR T candidate, is expected by mid-2022. Additionally, CYAD-101 demonstrated good tolerability in advanced metastatic colorectal cancer and will soon enter the KEYNOTE-B79 Phase 1b trial. The company also acquired a license for an antibody targeting TAG-72.
Celyad Oncology announced a Research & Development webinar on July 20th, 2021, at 11:30 a.m. EDT, focusing on advancements in its pipeline. The leadership team will discuss preclinical allogeneic CAR T assets using shRNA technology and updates on clinical programs, including the CYAD-211 candidate for relapsed/refractory multiple myeloma and CYAD-101 for metastatic colorectal cancer. Investors can register for the live webcast on the Celyad website, with a replay available afterward.
Celyad Oncology, a clinical-stage biotechnology company focused on CAR T therapies for cancer, announced that Dr. David Gilham will participate in a panel discussion titled “Cell Therapies in the Next Decade” on July 14, 2021, at the William Blair Biotech Focus Conference. The event will be held virtually from July 14-15, and the management team will also engage in one-on-one investor meetings. A live audio webcast of the discussion will be available on the company’s website. Celyad continues to develop innovative cancer treatments through its extensive CAR T pipeline.
Celyad Oncology (CYAD) announced a capital increase of 306,800 new shares on June 30, 2021, through Lincoln Park Capital Fund, LLC and Jefferies LLC. This transaction raises the company's share capital to 53,912,224.33 EUR, now represented by 15,493,956 shares. The number of shares with single voting rights totals 13,125,931, while shares with double voting rights amount to 2,368,025. The total of diluted shares is 17,416,379. This disclosure complies with Belgian law regarding the transparency of major participations in trading companies.
Celyad Oncology has announced promising preliminary data from the Phase 1 IMMUNICY-1 trial of CYAD-211 for treating relapsed/refractory multiple myeloma. The treatment was generally well-tolerated at the first two dose levels, with no Graft-versus-Host Disease and two partial responses among five evaluable patients. All patients showed cell engraftment after the second dose. Management plans to provide additional results in the second half of 2021 and highlighted the potential of shRNA technology for allogeneic CAR T therapies.
Celyad Oncology announced a capital increase on May 31, 2021, issuing 182,000 new shares through its Open Market Sale Agreement with Jefferies LLC. This brings the company's total share capital to 52,844,560.33 EUR and increases total shares to 15,187,156. Following the increase, the total number of diluted shares stands at 17,114,912. This move follows Article 15 of Belgian law concerning the disclosure of major participations in publicly traded companies.
Celyad Oncology SA, focused on CAR T therapies for cancer, will present at multiple conferences in June 2021. The presentations will be led by CEO Filippo Petti at events including the Jefferies Virtual Healthcare Conference, William Blair Annual Growth Stock Conference, and JMP Securities Life Sciences Conference. Notably, funding from Walloon Region has been received to support ongoing CAR T therapy programs. Celyad is developing both allogeneic and autologous CAR T candidates targeting hematological malignancies and solid tumors.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) received a transparency notification indicating that Victory Capital Management Inc. has crossed the 5% threshold in voting rights, holding 713,214 shares (4.11% of total shares) as of May 13, 2021. The notification reflects a downward crossing of the statutory threshold due to acquisition or disposal of voting securities. Victory Capital operates through multiple controlled undertakings, and it can exercise voting rights at its discretion.